Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season.
Saved in:
| Title: | Public health impact of RSV vaccination among adults aged 60 years and older in the United States using real-world evidence from the initial post-introduction season. |
|---|---|
| Authors: | Verelst F; Global RWE & Health Outcomes Research, GSK, Wavre, Belgium., Singer D; US Health Economics and Outcomes Research, GSK, Philadelphia, PA, USA., Graham J; Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA., Grace M; Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA., La EM; US Health Economics and Outcomes Research, GSK, Philadelphia, PA, USA., Biundo E; Global RWE & Health Outcomes Research, GSK, Wavre, Belgium. |
| Source: | Expert review of vaccines [Expert Rev Vaccines] 2025 Dec; Vol. 24 (1), pp. 797-806. Date of Electronic Publication: 2025 Aug 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101155475 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8395 (Electronic) Linking ISSN: 14760584 NLM ISO Abbreviation: Expert Rev Vaccines Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
